Neoadjuvant nivolumab plus ipilimumab in microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) rectal tumors: ECOG-ACRIN EA2201

被引：0
|
作者：
Ciombor, K. K. [1 ]
Hong, S. [2 ]
Eng, C. [3 ]
Yao, X. [4 ]
You, N. [5 ]
Das, P. [6 ]
Chakravarthy, A. [7 ]
O'Dwyer, P. J. [8 ]
机构：
[1] Vanderbilt Univ, Med Ctr, Internal Med Hematol Oncol Dept, Preston Canc Res Bldg, Nashville, TN USA
[2] Dana Farber Canc Inst, Data Sci, Boston, MA USA
[3] Vanderbilt Ingram Canc Ctr, Hematol Oncol Dept, Nashville, TN USA
[4] Cleveland Clin Florida, Oncol, Weston, FL USA
[5] Univ Texas MD Anderson Canc Ctr, Colorectal Surg, Houston, TX USA
[6] Univ Texas MD Anderson Canc Ctr, Radiol Oncol, Houston, TX USA
[7] Vanderbilt Univ, Med Ctr, Radiat Oncol, Nashville, TN USA
[8] ECOG ACRIN Canc Res Grp, Med Oncol Dept, Philadelphia, PA USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.249
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
242MO
引用
收藏
页码：S104 / S104
页数：1
相关论文
共 50 条
  • [31] Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142.
    Overman, Michael J.
    Lenz, Heinz-Josef
    Andre, Thierry
    Aglietta, Massimo
    Wong, Mark Ka
    Luppi, Gabriele
    Van Cutsem, Eric
    McDermott, Raymond S.
    Hendlisz, Alain
    Cardin, Dana Backlund
    Morse, Michael
    Neyns, Bart
    Hill, Andrew Graham
    Limon, M. Luisa
    Garcia-Alfonso, Pilar
    Krishnamurthy, Anuradha
    Chen, Franklin
    Abdullaev, Sandzhar
    Soleymani, Samira
    Lonardi, Sara
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [32] Combination of nivolumab (nivo) 1 ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 Study
    Lonardi, S.
    Andre, T.
    Wong, K. Y. M.
    Morse, M.
    McDermott, R.
    Hill, A.
    Hendlisz, A.
    Lenz, H.
    Leach, J.
    Moss, R. A.
    Cao, Z. A.
    Ledeine, J.
    Kopetz, S.
    Overman, M.
    ANNALS OF ONCOLOGY, 2017, 28 : 3 - 3
  • [33] SYSTEMATIC AND STRUCTURED REVIEWS OF THE DISEASE BURDEN IN PATIENTS WITH MICROSATELLITE INSTABILITY HIGH (MSI-H) OR MISMATCH REPAIR DEFICIENT (DMMR) COLORECTAL CANCER (CRC)
    Amonkar, M.
    Chase, M.
    Takyar, J.
    Sharma, S.
    VALUE IN HEALTH, 2021, 24 : S24 - S24
  • [34] Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): The GARNET study.
    Oaknin, Ana
    Pothuri, Bhavana
    Gilbert, Lucy
    Sabatier, Renaud
    Ghamande, Sharad A.
    Gravina, Adriano
    Calvo, Emiliano
    Banerjee, Susana N.
    Miller, Rowan
    Pikiel, Joanna
    Mirza, Mansoor Raza
    Duan, Tao
    Zildjian, Sybil
    Zografos, Eleftherios
    Veneris, Jennifer Taylor
    Tinker, Anna
    Powell, Matthew A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [35] Nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical update.
    Lenz, Heinz-Josef
    Lonardi, Sara
    Zagonel, Vittorina
    Van Cutsem, Eric
    Limon, M. Luisa
    Wong, Mark
    Hendlisz, Alain
    Aglietta, Massimo
    Garcia-Alfonso, Pilar
    Neyns, Bart
    Gelsomino, Fabio
    Cardin, Dana Backlund
    Dragovich, Tomislav
    Shah, Usman
    Yang, Jing
    Ledeine, Jean-Marie
    Overman, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [36] Quality of life (QoL) in patients (pts) with microsatellite instability (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) alone or in combination with ipilimumab (IPI): CheckMate 142
    Van Cutsem, E.
    Dixon, M.
    Taylor, F.
    Sun, X.
    Yip, C.
    Blum, S. I.
    ANNALS OF ONCOLOGY, 2021, 32 : S553 - S553
  • [37] Phase 2 study of pembrolizumab-based combination therapy in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) stage IV colorectal cancer (CRC)
    Andre, Thierry
    Sposetti, Caterina
    Gumus, Mahmut
    Ahn, Joong Bae
    Wyrwicz, Lucjan
    Kwiatkowski, Mariusz
    Kim, Jong Gwang
    Yalcin, Suayib
    Sendur, Mehmet A. N.
    Odeleye-Ajakaye, Amos
    Leconte, Pierre
    Fogelman, David R.
    Kim, Tae Won
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [38] Retifanlimab in patients with recurrent microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) endometrial cancer: Final results from the POD1UM-101 study (Cohort H)
    Berton-Rigaud, D.
    Pautier, P.
    Lorusso, D.
    Gennigens, C.
    Gladieff, L.
    Kryzhanivska, A.
    Bowman, J.
    Tian, C.
    Cornfeld, M.
    Van Gorp, T.
    ANNALS OF ONCOLOGY, 2023, 34 : S517 - S517
  • [39] Response to Nivolumab and Ipilimumab in Microsatellite Instability-High (MSI-H) Cervical Carcinoma with Acquired Resistance to Pembrolizumab: A Case Report and Literature Review
    Gim, Gahyun
    Kim, Yeseul
    Park, Yeonggyeong
    Kim, Min Jeong
    Nam, Myungwoo
    Yang, Woojung
    Duarte, Samantha E.
    Jung, Chan Mi
    Vagia, Elena
    Viveiros, Pedro
    Chae, Young Kwang
    ONCOLOGIST, 2022, 27 (07): : 525 - 531
  • [40] Pembrolizumab for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced endometrial cancer: Long-term follow-up results from KEYNOTE-158
    O'Malley, D.
    Bariani, G. M.
    Cassier, P. A.
    Marabelle, A.
    Hansen, A. R.
    De Jesus-Acosta, A.
    Miller, W. H.
    Safra, T.
    Italiano, A.
    Mileshkin, L.
    Yao, L.
    Gozman, A.
    Jin, F. J.
    Maio, M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S796 - S797
12345